Huntington's Disease: Can Mice Lead the Way to Treatment?

被引:181
作者
Crook, Zachary R. [1 ]
Housman, David [1 ]
机构
[1] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA
关键词
TRANSGENIC MOUSE MODEL; NEURONAL INTRANUCLEAR INCLUSIONS; CAG REPEAT INSTABILITY; CORTICAL SYNAPTIC PLASTICITY; GENE-EXPRESSION CHANGES; HUMAN MUTANT HUNTINGTIN; KNOCK-IN; STRIATAL NEURONS; MOTOR DYSFUNCTION; QUINOLINIC ACID;
D O I
10.1016/j.neuron.2010.12.035
中图分类号
Q189 [神经科学];
学科分类号
071006 [神经生物学];
摘要
Mouse models for Huntington's Disease (HD) and HD patients demonstrate motor and behavioral dysfunctions, such as progressive loss of coordination and memory, and share similar transcriptional profiles and striatal neuron atrophy. Clear differences between the mouse and human diseases include almost complete striatal degeneration and rarity of intranuclear inclusions in HD, and the fact that mice expressing full-length mutant huntingtin do not demonstrate a shortened life span characteritstic of HD. While no clinical interventions tested in mouse models to date have delayed disease progression, the mouse models provide an invaluable tool for both investigating the underlying pathogenic processes and developing new effective therapies. Inherent differences between humans and mice must be considered in the search for efficacious treatments for HD, but the striking similarities between human HD and mouse models support the view that these models are a biologically relevant system to support the identification and testing of potential clinical therapies.
引用
收藏
页码:423 / 435
页数:13
相关论文
共 141 条
[1]
Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease [J].
Andreassen, OA ;
Dedeoglu, A ;
Ferrante, RJ ;
Jenkins, BG ;
Ferrante, KL ;
Thomas, M ;
Friedlich, A ;
Browne, SE ;
Schilling, G ;
Borchelt, DR ;
Hersch, SM ;
Ross, CA ;
Beal, MF .
NEUROBIOLOGY OF DISEASE, 2001, 8 (03) :479-491
[2]
[Anonymous], 2002, Huntington's disease
[3]
BEAL MF, 1991, J NEUROSCI, V11, P1649
[4]
REPLICATION OF THE NEUROCHEMICAL CHARACTERISTICS OF HUNTINGTONS-DISEASE BY QUINOLINIC ACID [J].
BEAL, MF ;
KOWALL, NW ;
ELLISON, DW ;
MAZUREK, MF ;
SWARTZ, KJ ;
MARTIN, JB .
NATURE, 1986, 321 (6066) :168-171
[5]
BEAL MF, 1993, J NEUROSCI, V13, P4181
[6]
Genetic Knock-Down of HDAC7 Does Not Ameliorate Disease Pathogenesis in the R6/2 Mouse Model of Huntington's Disease [J].
Benn, Caroline L. ;
Butler, Rachel ;
Mariner, Lydia ;
Nixon, Jude ;
Moffitt, Hilary ;
Mielcarek, Michal ;
Woodman, Ben ;
Bates, Gillian P. .
PLOS ONE, 2009, 4 (06)
[7]
Global changes to the ubiquitin system in Huntington's disease [J].
Bennett, Eric J. ;
Shaler, Thomas A. ;
Woodman, Ben ;
Ryu, Kwon-Yul ;
Zaitseva, Tatiana S. ;
Becker, Christopher H. ;
Bates, Gillian P. ;
Schulman, Howard ;
Kopito, Ron R. .
NATURE, 2007, 448 (7154) :704-U11
[8]
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease [J].
Bjorkqvist, Maria ;
Wild, Edward J. ;
Thiele, Jenny ;
Silvestroni, Aurelio ;
Andre, Ralph ;
Lahiri, Nayana ;
Raibon, Elsa ;
Lee, Richard V. ;
Benn, Caroline L. ;
Soulet, Denis ;
Magnusson, Anna ;
Woodman, Ben ;
Landles, Christian ;
Pouladi, Mahmoud A. ;
Hayden, Michael R. ;
Khalili-Shirazi, Azadeh ;
Lowdell, Mark W. ;
Brundin, Patrik ;
Bates, Gillian P. ;
Leavitt, Blair R. ;
Moller, Thomas ;
Tabrizi, Sarah J. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2008, 205 (08) :1869-1877
[9]
Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease Mice [J].
Boudreau, Ryan L. ;
McBride, Jodi L. ;
Martins, Ines ;
Shen, Shihao ;
Xing, Yi ;
Carter, Barrie J. ;
Davidson, Beverly L. .
MOLECULAR THERAPY, 2009, 17 (06) :1053-1063
[10]
Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin [J].
Boutell, JM ;
Thomas, P ;
Neal, JW ;
Weston, VJ ;
Duce, J ;
Harper, PS ;
Jones, AL .
HUMAN MOLECULAR GENETICS, 1999, 8 (09) :1647-1655